849 reports of this reaction
4.2% of all BENDAMUSTINE HYDROCHLORIDE reports
#2 most reported adverse reaction
PYREXIA is the #2 most commonly reported adverse reaction for BENDAMUSTINE HYDROCHLORIDE, manufactured by Cephalon, LLC. There are 849 FDA adverse event reports linking BENDAMUSTINE HYDROCHLORIDE to PYREXIA. This represents approximately 4.2% of all 20,231 adverse event reports for this drug.
Patients taking BENDAMUSTINE HYDROCHLORIDE who experience pyrexia should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
PYREXIA is moderately reported among BENDAMUSTINE HYDROCHLORIDE users, representing a notable but not dominant share of adverse events.
In addition to pyrexia, the following adverse reactions have been reported for BENDAMUSTINE HYDROCHLORIDE:
The following drugs have also been linked to pyrexia in FDA adverse event reports:
PYREXIA has been reported as an adverse event in 849 FDA reports for BENDAMUSTINE HYDROCHLORIDE. This does not prove causation, but indicates an association observed in post-market surveillance data.
PYREXIA accounts for approximately 4.2% of all adverse event reports for BENDAMUSTINE HYDROCHLORIDE, making it one of the most commonly reported side effect.
If you experience pyrexia while taking BENDAMUSTINE HYDROCHLORIDE, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.